A comparative pharmacokinetic study: 5 Fluorouracil (5FU) provided as patient specific individual doses and as standard doses according to a 'dose banding' principle

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN46112469

Enrollment

Registered

2005-09-30

Start date

2002-03-01

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer: Breast Cancer Breast cancer

Interventions

Randomised controlled trial

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women with breast cancer who are receiving adjuvant therapy.

Exclusion criteria

Exclusion criteria: Patients on reduced doses of FEC chemotherapy, with known liver metastases, who have received chemotherapy for previous malignancies.

Design outcomes

Primary

Measure	Time frame
The comparative plasma concentration profiles (Cmax, AUC) in patients receiving dose-banded and individually prepared doses of 5 Fluorouracil.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026